[HTML][HTML] Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in …

…, S Olszevicki, M Salazar, A Calabria, L Regairaz… - …, 2021 - thelancet.com
Background A first-dose of various vaccines provides acceptable protection against infections
by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant …

Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency

…, T Witte, KW Sykora, S Goldacker, L Regairaz… - Journal of Allergy and …, 2015 - Elsevier
Background Common variable immunodeficiency (CVID) is usually well controlled with
immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a …

Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases

…, S Espinosa, I Barlan, N Pérez, L Regairaz… - Journal of Allergy and …, 2016 - Elsevier
Background Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused
by inborn errors of the phagocyte nicotinamide adenine dinucleotide phosphate oxidase …

Clinical and genotypic spectrum of chronic granulomatous disease in 71 Latin American patients: first report from the LASID registry

…, A Lozano, M Galicchio, L Regairaz… - Pediatric blood & …, 2015 - Wiley Online Library
Aim We analyzed data from 71 patients with chronic granulomatous disease (CGD) with a
confirmed genetic diagnosis, registered in the online Latin American Society of Primary …

[HTML][HTML] Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in …

…, A Gaiano, ANV Baino, L Regairaz… - The Lancet Regional …, 2022 - thelancet.com
Background Although paediatric clinical presentations of COVID-19 are usually less severe
than in adults, serious illness and death have occurred. Many countries started the …

[HTML][HTML] Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak …

…, A Gaiano, M Salazar, L Regairaz… - The Lancet Regional …, 2023 - thelancet.com
Background After primary vaccination schemes with rAd26-rAd5 (Sputnik V), ChAdOx1
nCoV-19, BBIBP-CorV or heterologous combinations, the effectiveness of homologous or …

[HTML][HTML] Risk factors for COVID-19 mortality: The effect of convalescent plasma administration

MR Salazar, SE Gonzalez, L Regairaz, NS Ferrando… - PLoS …, 2021 - journals.plos.org
Background Convalescent plasma, widely utilized in viral infections that induce neutralizing
antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might …

Timing of convalescent plasma administration and 28-day mortality in COVID-19 pneumonia

SE González, L Regairaz, MR Salazar… - Journal of …, 2022 - journals.sagepub.com
This is a multicenter cohort study including consecutive, hospitalized patients ≥18 years, with
moderate to severe COVID-19, carried out to evaluate the relationship between the timing …

Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in …

…, A Gómez Raccio, G Belardinelli, L Regairaz… - Journal of clinical …, 2013 - Springer
Purpose Several studies have shown that subcutaneous immunoglobulin (SCIG) infusions
demonstrate similar efficacy to intravenous Ig (IVIG) in preventing infections in patients with …

Leukocyte adhesion deficiency type 1 (LAD1) with expressed but nonfunctional CD11/CD18

D Cabanillas, L Regairaz, C Deswarte… - Journal of clinical …, 2016 - Springer
To the Editor, We report here a case of leukocyte adhesion deficiency (LAD) type 1 in a 4-year-old
girl (Amerindian from Argentina), the only child of consanguineous parents (Fig. 1). …